Dogodan Therapeutics
Thomas Tibbitts, CEO and Head of Research and Development. Over twenty years experience in the pharmaceutical industry. Goldfinch Bio SVP Computational Research, launched the Kidney Genome Atlas. Third Rock Ventures team launching Goldfinch Bio with $55M series A. Infinity Pharmaceuticals, multiple drug programs over a decade Copiktra (duvelisib), approved to treat CLL and SLL, Eganelisib (IPI-549), for the treatment triple-negative breast cancer. PhD Biophysics from Brandeis University.
This person is not in any offices
Dogodan Therapeutics
1 followers
At DTI we Integrate the latest knowledge in genomics, biology and computing to bring revolutionary, multifaceted genomic medicines to patients suffering with respiratory infections and diseases of the lung.